CRSP vs. REGN: A Head-to-Head Stock Comparison

Updated on October 12, 2025

Here’s a clear look at CRSP and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	CRSP	REGN
Company Name	CRISPR Therapeutics AG	Regeneron Pharmaceuticals, Inc.
Country	Switzerland	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	6.98 billion USD	59.76 billion USD
Exchange	NasdaqGM	NasdaqGS
Listing Date	October 19, 2016	April 2, 1991
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of CRSP and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

CRSP vs. REGN: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	CRSP	REGN
5-Day Price Return	5.44%	-6.02%
13-Week Price Return	27.80%	2.04%
26-Week Price Return	135.09%	-7.66%
52-Week Price Return	68.78%	-43.39%
Month-to-Date Return	18.47%	0.28%
Year-to-Date Return	95.07%	-20.84%
10-Day Avg. Volume	2.82M	1.23M
3-Month Avg. Volume	3.05M	1.10M
3-Month Volatility	69.28%	31.59%
Beta	1.73	0.37

Profitability

Return on Equity (TTM)

CRSP

-25.25%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

CRSP has a negative Return on Equity of -25.25%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

REGN

15.11%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

CRSP vs. REGN: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

CRSP

-1,229.43%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

CRSP has a negative Net Profit Margin of -1,229.43%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

REGN

31.37%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

CRSP vs. REGN: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

CRSP

-1,451.95%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

CRSP has a negative Operating Profit Margin of -1,451.95%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

REGN

27.02%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

CRSP vs. REGN: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	CRSP	REGN
Return on Equity (TTM)	-25.25%	15.11%
Return on Assets (TTM)	-21.52%	11.81%
Net Profit Margin (TTM)	-1,229.43%	31.37%
Operating Profit Margin (TTM)	-1,451.95%	27.02%
Gross Profit Margin (TTM)	--	86.46%

Financial Strength

Current Ratio (MRQ)

CRSP

16.61

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

CRSP’s Current Ratio of 16.61 is in the upper quartile for the Biotechnology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

REGN

4.60

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

CRSP vs. REGN: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

CRSP

0.00

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

CRSP’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

REGN

0.09

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

CRSP vs. REGN: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

CRSP

13.24

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

CRSP’s Interest Coverage Ratio of 13.24 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

REGN

243.95

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.

CRSP vs. REGN: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	CRSP	REGN
Current Ratio (MRQ)	16.61	4.60
Quick Ratio (MRQ)	16.49	3.78
Debt-to-Equity Ratio (MRQ)	0.00	0.09
Interest Coverage Ratio (TTM)	13.24	243.95

Growth

Revenue Growth

CRSP vs. REGN: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

CRSP vs. REGN: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

CRSP

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

CRSP currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

CRSP vs. REGN: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

CRSP

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

CRSP has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

CRSP vs. REGN: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	CRSP	REGN
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

CRSP

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for CRSP is currently unavailable.

REGN

13.81

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.81 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

CRSP vs. REGN: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

CRSP

184.51

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

With a P/S Ratio of 184.51, CRSP trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

REGN

4.33

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.33 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

CRSP vs. REGN: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

CRSP

2.46

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

CRSP’s P/B Ratio of 2.46 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

REGN

1.89

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

CRSP vs. REGN: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	CRSP	REGN
Price-to-Earnings Ratio (TTM)	--	13.81
Price-to-Sales Ratio (TTM)	184.51	4.33
Price-to-Book Ratio (MRQ)	2.46	1.89
Price-to-Free Cash Flow Ratio (TTM)	64.39	17.32